en

PRODUCT DETAIL

WELIREG 40 mg filmom obalené tablety

Code 9027E
MA number EU/1/24/1893/002
Product Form: tbl flm 90 (3x30)x40 mg (blis.Al/Al)
MA Status: Ex - Conditional centralised marketing authorisation
Type of procedure: EU
MAH, country: Merck Sharp & Dohme B.V., Netherland
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX74 Belzutifan
Shelf life: 48
Container: blister Al/Al
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 12.02.2025
Validity: 12.02.2026
SmPC + PL: European Medicines Agency's database
Dokument: Welireg_Prirucka pre zdravotnickych pracovnikov.pdf  
Safety feature Yes
Data update: 17.02.2025
eu-flag.png sk-flag.png